Medical researchers at the University of Alberta have discovered a potential new drug target for multiple sclerosis that could prevent the physical disability associated with the disease.
In the first phase of MS, those with the condition have inflammation of their brain cells, resulting in continuous cycles of inflammation attacks and recovery periods. In the second phase of the disease, the inflammation isn’t as severe, but this is the stage where physical disability sets in due to the effects of substantial brain cells being killed in the first phase of the disease.
When immune cells become active due to inflammation, they can pass the blood brain barrier and enter the central nervous system. Some of these activated immune cells secrete a molecule, known as granzyme B, which can get inside neurons and wreak havoc, ultimately causing brain cell death. Granzyme B is found in MS brain lesions, especially in the early stages of inflammation. This molecule can get into brain cells through a “gatekeeper,” known as receptor M6PR.
Researchers with the Faculty of Medicine & Dentistry discovered in lab experiments that if they prevent this granzyme B from entering neurons, “we can also prevent the killing of neurons,” says principal investigator Fabrizio Giuliani, whose work was recently published in the peer-reviewed publication, The Journal of Immunology.
“It is this loss of brain cells in the long term that induces disability in those with MS,” he says. “This new drug target for MS is specific for the neurodegenerative processes following inflammation, which should address this long-term loss of brain cells.”
Giuliani, a researcher in the Division of Neurology and a practising neurologist, noted this latest research builds on previous findings by his colleagues within the faculty. Medical researcher and co-author Chris Bleackley made an earlier discovery about how granzyme B enters target cells through the receptor M6PR, while another faculty researcher discovered that the M6PR receptor is found mostly in neurons.
“We were just connecting the dots and said, ‘OK, if this receptor is expressed in neurons specifically and not expressed in other cells, is it possible that this is the mechanism that allows this granzyme B to get into human neurons and start killing brain cells?’ What we found is yes, this ‘death’ receptor allows this specific molecule to get in and that if you block the receptor, you also block the neurotoxic effect in neurons. This is an excellent example about collaboration with other researchers and translational research.”
Many existing MS treatments primarily target brain inflammation, which is very effective in the first phase of the disease but not as helpful once patients reach the second phase. Giuliani says what is needed are new medications that can either repair inflamed brain cells or prevent brain degeneration in the first place. He says this new drug target could do just that, by preventing brain cell death in the early stages of the disease.
With this new drug target, Giuliani adds that only a specific function of a cell would be blocked, not multiple functions of a cell. Many medications on the market block multiple functions of a specific type of cell. “We are blocking a specific function, not multiple pathways and eventually this strategy could reduce the side effects of new drugs.”
Giuliani and his fellow researchers are continuing their research in this area.
This research was supported through funding by the MS Society of Canada, the Canadian Institutes of Health Research, Alberta Innovates-Health Solutions and the University of Alberta Hospital Foundation.